[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100661421":3},{"organization":4,"outcomesModule":7,"designInfo":40,"detailedDescription":46,"studyPopulation":39,"armGroups":47,"interventions":54,"overallOfficials":39,"centralContacts":64,"locations":70,"responsibleParty":104,"collaborators":39,"id":106,"slug":107,"hasResults":108,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":108,"sex":114,"minAge":115,"maxAge":39,"enrollmentInfo":116,"targetDuration":39,"studyType":119,"phases":120,"briefSummary":122,"conditions":123,"keywords":39,"overallStatus":73,"whyStopped":39,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":145},{"fullName":5,"class":6},"Aktis Oncology, Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":20,"otherOutcomes":39},[9,13,17],{"measure":10,"description":11,"timeFrame":12},"Part 1: Occurrence of adverse events by severity and occurrence of serious adverse events (SAEs) in participants who received [225Ac]Ac-AKY-2519","An AE is defined as any untoward medical occurrence in a participant administered study drug, which does not necessarily have to have a causal relationship with the study drug. The number of patients experiencing an AE and the number of patients experiencing an SAE will be reported.","Up to 30 days following last administration of [225Ac]Ac-AKY-2519",{"measure":14,"description":15,"timeFrame":16},"Part 1: Occurrence of dose-limiting toxicity (DLT) in participants","Dose-limiting toxicities (DLTs) is defined as any predefined AE occurring during the DLT observation period, except those that are clearly and incontrovertibly due to extraneous circumstances. The number of patients who experience a DLT will be reported separately for each cohort and by dose level within each cohort","From first administration of [225Ac]Ac-AKY-2519 to the end of Cycle 1 (each cycle is 28 days)",{"measure":18,"description":19,"timeFrame":12},"Part 2: Objective Response Rate (ORR)","Part 2: Objective Response Rate (ORR) • Objective response rate is defined as the percentage of patients who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), as determined by the investigator based on RECIST v1.1. Up to 30 days following last administration of \\[225Ac\\]Ac-AKY-2519",[21,25,28,32,35,37],{"measure":22,"description":23,"timeFrame":24},"Part 1: Occurrence of adverse events by severity and occurrence of serious adverse events (SAEs) in participants who received [64Cu]Cu AKY 2519","An AE is defined as any untoward medical occurrence in a participant administered study drug, which does not necessarily have to have a causal relationship with the study drug. The number of patients experiencing an AE will be reported.","Up to 6 days following last administration of [64Cu]Cu AKY 2519 or, if earlier, until the first dose of [225Ac]Ac-AKY-2519",{"measure":26,"description":27,"timeFrame":12},"Part 1: Objective Response Rate (ORR)","ORR is defined as the percentage of patients who achieved a best overall response of confirmed Complete Response (CR) or Partial Response (PR), as determined by the investigator based on RECIST v1.1 or PCWG3-modified RECIST v1.1.",{"measure":29,"description":30,"timeFrame":31},"Part 2: Duration of Response (DoR)","Duration of Response (DoR) is defined as the time from the date of the first documentation of objective response (complete response \\[CR\\] or partial response \\[PR\\]) to the date of the first objective documentation of progressive disease (PD) or death due to any cause.","Up to 5 years after first administration",{"measure":33,"description":34,"timeFrame":31},"Part 2: Progression-Free Survival (PFS)","PFS is defined as the time from treatment initiation to the first documented disease progression per RECIST v1.1 or death due to any cause, whichever occurs first.",{"measure":36,"description":23,"timeFrame":24},"Part 2: Occurrence of adverse events by severity and occurrence of serious adverse events (SAEs) in participants who received [64Cu]Cu AKY 2519",{"measure":38,"description":11,"timeFrame":12},"Part 2: Occurrence of adverse events by severity and occurrence of serious adverse events (SAEs) in participants who received [225Ac]Ac-AKY-2519",null,{"allocation":41,"interventionModel":42,"interventionModelDescription":39,"primaryPurpose":43,"observationalModel":39,"timePerspective":39,"maskingInfo":44},"NA","SINGLE_GROUP","TREATMENT",{"masking":45,"maskingDescription":39,"whoMasked":39},"NONE","This Phase 1b study consists of two parts.\n\nPart 1 is the dose escalation portion and will investigate ascending doses of \\[225Ac\\]Ac-AKY-2519 in patients with locally advanced or metastatic solid tumors, including non-small cell lung cancer (NSCLC), extensive stage-small cell lung cancer (ES-SCLC), metastatic castration-resistant prostate cancer (mCRPC), head and necks squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC), and colorectal cancer (CRC). Part 1 will also incorporate a backfill strategy to evaluate two dose levels further.\n\nPart 2 is the dose expansion portion and aims to assess the efficacy of \\[225Ac\\]Ac-AKY-2519 in two separate cohorts by indication:\n\n* Cohort A: NSCLC\n* Cohort B: Other solid tumors",[48],{"label":49,"type":50,"description":39,"interventionNames":51},"[225Ac]Ac-AKY-2519","EXPERIMENTAL",[52,53],"Drug: [225Ac]Ac-AKY-2519 (therapeutic)","Drug: [64Cu]Cu-AKY-2519 (imaging)",[55,60],{"type":56,"name":57,"description":58,"armGroupLabels":59,"otherNames":39},"DRUG","[225Ac]Ac-AKY-2519 (therapeutic)","\\[225Ac\\]Ac-AKY-2519 Injection",[49],{"type":56,"name":61,"description":62,"armGroupLabels":63,"otherNames":39},"[64Cu]Cu-AKY-2519 (imaging)","\\[64Cu\\]Cu-AKY-2519 Injection",[49],[65],{"name":66,"role":67,"phone":68,"phoneExt":39,"email":69},"TIffany Wang, MD","CONTACT","857-239-5333","AKY-2519-02inquiries@aktisoncology.com",[71,90],{"facility":72,"status":73,"city":74,"state":75,"zip":76,"country":77,"countryCode":78,"cosmosGeoPoint":79,"geoPoint":84,"contacts":85},"Biogenix Molecular, LLC","RECRUITING","Miami","Florida","33165","United States","US",{"type":80,"coordinates":81},"Point",[82,83],-80.19366,25.77427,{"lat":83,"lon":82},[86],{"name":87,"role":67,"phone":88,"phoneExt":39,"email":89},"Study Coordinator","786-791-1799","rrippin@cira-health.com",{"facility":91,"status":73,"city":92,"state":93,"zip":94,"country":77,"countryCode":78,"cosmosGeoPoint":95,"geoPoint":99,"contacts":100},"MD Anderson Cancer Center","Houston","Texas","77030",{"type":80,"coordinates":96},[97,98],-95.36327,29.76328,{"lat":98,"lon":97},[101],{"name":87,"role":67,"phone":102,"phoneExt":39,"email":103},"713-792-1478","NAVelez@mdanderson.org",{"type":105,"investigatorFullName":39,"investigatorTitle":39,"investigatorAffiliation":39,"oldNameTitle":39,"oldOrganization":39},"SPONSOR","100661421","phase-1-a-study-of-225acac-aky-2519-in-patients-with-b7-h3-expressing-solid-tumors-100661421",false,"NCT07887971","A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors","BActinium-2: A Phase 1b, 2 Part, Multicenter, Open Label Study to Evaluate the Safety and Efficacy of Intravenous Administration of a B7-H3 Radiopharmaceutical ([225Ac]Ac AKY 2519) in Participants With B7-H3 Imaging Positive Solid Tumors","BActinium-2","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Histologic or cytologic confirmation of locally advanced or metastatic NSCLC, ES-SCLC, HNSCC, ESCC, CRC or prostatic adenocarcinoma\n* Radiologic confirmation on CT of at least one measurable tumor lesion per RECIST v1.1\n* ECOG Performance Status of 0 or 1\n* Adequate end-organ function\n* Ability to give informed consent and comply with study requirements\n* Patients with CNS metastases are eligible if they have received therapy and are neurologically stable, asymptomatic and not receiving corticosteroids\n\nExclusion Criteria:\n\n* Prior treatment with a B7-H3 targeted therapy\n* Prior treatment with a targeted radiotherapy\n* Received an investigational agent within the previous 28 days\n* Prior treatment with a cytotoxic chemotherapy, targeted therapy, biologic agent, immunotherapy or external-beam radiotherapy within the previous 28 days\n* Impaired cardiac function or clinically significant cardiac disease\n* Concurrent serious medical condition that would impair study participation or impact the assessment of treatment related toxicity","ALL","18 Years",{"count":117,"type":118},152,"ESTIMATED","INTERVENTIONAL",[121],"PHASE1","This is a Phase 1b, 2-part, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of \\[64Cu\\]Cu-AKY-2519 and\u002For \\[225Ac\\]Ac-AKY-2519, as well as the preliminary anti-tumor activity of \\[225Ac\\]Ac-AKY-2519 in participants with B7-H3 imaging positive solid tumors.",[124,125,126,127,128,129,130,131,132,133,134,135],"NSCLC","NSCLC (Advanced Non-small Cell Lung Cancer)","ES-SCLC","Small Cell Lung Cancer Extensive Stage","B7H3","Prostate Cancer","HNSCC","mCRPC (Metastatic Castration-resistant Prostate Cancer)","Head Neck Cancer Squamous Cell Metastatic","ESCC or Esophageal Adenosquamous Carcinoma","CRC","CRC (Colorectal Cancer)","2026-10-30",{"date":138,"type":139},"2026-11-02","ACTUAL",{"date":141,"type":118},"2026-11",{"date":143,"type":118},"2033-12",{"name":5,"class":6},2]